Skip to main
ALEC
ALEC logo

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Alector Inc. is strategically targeting neurodegeneration through innovative therapies that enhance immune function in the brain, with a robust pipeline including programs such as AL137, AL050, and ADP064-ABC, which address significant indications. The company's proprietary ABC platform has demonstrated a strong ability to penetrate the central nervous system (CNS) and has shown favorable safety signals, potentially leading to significant clinical advancements. Early proof-of-concept data from these programs may present substantial upside opportunities for the company, given the increasing standardization of Alzheimer’s disease biomarkers, which could bolster the likelihood of meaningful clinical outcomes.

Bears say

Alector's stock outlook has been negatively impacted by the failure of the INFRONT-3 trial for latozinemab, which did not meet its primary endpoint and introduced additional translational biology risks. This setback raises concerns about the efficacy of Alector's therapies and underscores the inefficiencies in progranulin transport, potentially jeopardizing revenue projections for key products AL001 and AL002. Additionally, the company's reliance on successful clinical study outcomes and regulatory approvals, along with risks of delays and unexpected adverse effects, further compounds the uncertainties surrounding its financial viability.

Alector Inc (ALEC) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 5 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.